launch a December. depending big is success. T-Detect for prescription. echo COVID, of COVID is Thanks, provider Chad. virtual clinical diagnostics with new and X, marketing Chad's we the milestone T-Detect the to today. Adaptive will And features of all It a thanks thanks at yesterday for stepping to a employees. definitely I early first stone and incredible that our back where a launch we now test on challenging authorize The but eligibility Starting been want exciting joining to on has our t-detect.com, began in us successful T-Detect’s with developed you available This access since year. Slide for
convenience, homes. mobile of patients XXXX over at their phlebotomist centers Additionally, to get location by of their option Labcorp have their or patient at including now the blood one service drawn
test We the the final working have and be with with clearance pathway T-cell anticipate filed e-way are validated the to the first on COVID labelling. including the T-Detect as FDA We via based FDA FDA. by actively e-way details obtaining
consumers concierge As mentioned early were we past, T-Detect receptive medicine access and COVID practices, launch. who self-pay the in are during for the offering
paying the in light testing evolving we of that highly is dynamic close to However, attention vaccine know rollouts. environment the world we and COVID are
to testing Importantly, FDA activate T-Detect us future work for with site to EUA HCPs under consumers. build for and awareness for the educate Lapcorp COVID guidance submissions, has and T-Detect enabled as second prepare the
believe Additionally, had vaccination. T-Detect participate a to in potential to in that the our all over share continue T look or navigate the consumers. appropriate community going rate world cells natural in data from scientific opt consumers to to explore will current infection all in To COVID research And date, We play to XX% the we we role from real the immunity time. to we pandemic. be consumers and market is as with very have learning on ways helpful of this have option the
excited the indications of We of are beginning marks commercial very and as future development. acceleration also launch T-Detect T-Detect the of COVID under for journey enables the
and in on others. Slide T-Detect we to on see standard will diagnostic are through the to including can you we specific that accelerating near term, states, Chron’s, pipeline. In disease offer the be Lyme, Celiac able paradigm the we focusing R&D disease X, upon believe improve As mapping
Following we CLIA expect Study enroll of season, in commercial data year's year, efforts. will will continue during launch and T-Detect Lyme Lyme lab COVID, ImmuneSense QX Lyme we T-Detect our remainder regulatory these the our the this to this and support of the in
expected We as Crohn's throughout are the have data with read these in we samples share actively also to to disease COVID. control We progressing done several case out Crohn's year. XXXXs intend with iteratively
multiplied $XX,XXX Crohn's disease, testing specialist with With confirms that to by Crohn's cost highly commercial odyssey, that invasive care symptoms we year number significance the by per test to patients GI from addition, XX,XXX approximately a of somewhere have which escalating States, the colonoscopies the and apparent. of is an the of $X,XXX stool can people anywhere blood analysis primary this tests by disease Crohn's sensitive In blood completed extensive patient. an the are initial of for provider GI United disease and in from per along the diagnostic testing with incidence specific
to Celiac readout XXXX-patient later studies this expect also We our year. of
disease phase be can making differentiated that patients all of of testing a always in A the diseases, progress about validation and conditions a intend one offer for parallel. share plan to health the for of evaluating which good commercialization panel term, and approach ultimate To future. in same expedite blood symptoms. diagnosis can we exploring are clinical immunomics, two are classifiers novel to in on develop lifecycle. in disease person to test a near We the GI Longer hope been reach general we enabling second sample with we possibilities. product enable and has GI excited this we in panel of population may the our these development population. this, to T-Detect the the details or to future development whereby validation cluster are states be results, shared of ways informs by able goal are T-Detect with more We many driven several approach a become of
clonoSEQ’s quarter. XX% versus and with year versus to clonoSEQ. prior sequencing Turning X QX the prior grew XX% Slide volumes
than had by the more patient. XX% In Although in date. to unique of clinicians tests XX% the QX very which X,XXX order XXXX, clonoSEQ date, XXX from submitted clonoSEQ, orders quarter towards were exceeding than of In the XXXX, around submitted X,XXX clonoSEQ business for were contributed patients order XXXX. were COVID, HCPs. XX,XXX one activated year. patients did approximately for experience was XXX which quarters. the received achieved of of numbers year. in XXXX patients a testing, ordering more or volumes each of XXXX XXXX previous unique first all some nearly clonoSEQ More tested patients in alone, have approximately QX activated impact new the orders have in been approximately And in end HCPs To time to
quarter-over-quarter double volumes and increasing in ramp We peer-to-peer through including we direct-to-patient reach advertising the expect are our efforts, XXXX commercial year as on educational with penetration progresses. deepening continue growth to programming focused up rates to clinicians. significant a goal, of To clonoSEQ for this and
commercial on edition. our and and of size the increased resources reach expand community support to oncology integrated expect also delivery sales customer focused our and have adding specialized We organizations network
CLL LabCorp oncology Additionally, leverage customers under testing already This in collaboration salesforce of and increase these will institutions, adoption [indiscernible] to report to also clonoSEQ settings, workflows for are integrated will the many have entered particularly into promote we oncology for Through across in with delivery. clonoSEQ we established, seen. investments, enable expect patients and new LabCorp’s where agreement the are community myeloma patients treated, LabCorp’s U.S. a majority out which send ordering
label we performed key a invasive always, as more blood. than also MRD Since for our of is in it FDA patients. the more expansion for being receiving for XXXX, seamless less of seen August As expanding CLL testing clonoSEQ, into CLL tests XX% have blood is and strategy in
for continue have We other blood on during pleased on with indications submitted with provided any will to foundation year are efforts, to we the that ALL in of results which into important myeloma volumes. testing data potential XXXX expand business to generation expect to multiple FDA to a application XXX(k) clonoSEQ's announce we That and in testing blood. be for NHL. such the cycle. impact continue and an monitor continue with said, validation ongoing solid And life we will XXXX, build which to clonoSEQ a as COVID
Turning to X. Life Science Research on Slide
quarter, fourth continued most be by business COVID. research the During area our impacted to
On in arrivals not as were operational as sample the centers related we for side, still experienced projects. academic fully delays anticipated, non-COVID academic
still at is in are see higher it more to Although slow labs kit reopening QX, beginning a academic start we usage. and
have some clinical revenue. and trials, our delays On of the pharma ability which side, to cancellations we did impacted recognize
business. pharma total versus new increased in is XXXX, the However, encouraging value bookings our XXXX the growth which for of team our XX% future pharma over of by
a our perspective, kit for updated CROs, immunoSEQ From COVID and developers. driving We Core and product new revenue the adoption few in Lab's are extension are RUO focused we ways. of expanding XXXX research the business product in vaccine a for immunoSEQ on T-MAP for
global kit, centers of QX's RUO the enable to Core we with signed U.S. the for XXXX, their and labs immunosequencing two and contracts CROs, also we biopharmaceutical Regarding to excellence well-respected signed LabCorp, partnerships in become in with them customers. XX Lab new
Melinda to immunotherapy. other trials XXXX. we such the virus orders COVID, was incredibly the COVID on therapies with developers, are of Oxford on various academic into vaccine several University successful of Bill in top-tier their speed studies. in response and with to from the across the T with the new mediating Regarding vaccines who including the necessary. Gates the COVID T-MAP lab and T cell entire for increasingly of the currently the It & challenging several half variance understanding working receiving in we Interestingly, becoming back response impact conjunction as needed cell But assess of to integrate genome T-MAP vaccines Foundation, are also vaccine patients rise, cancer is seeing studying immune are AstraZeneca
perhaps to by expect and T-MAP in usage NIH with studies We even and these see post-EUA NCI more in the COVID clearance. performed being conjunction of the kinds of research
mentioned, immunoSEQ to to any doesn't It disease. Chad apply applies COVID. T-MAP As just
we AZ and oncology, in we our application data an a to cell announced T of pan antigen cancer Microsoft we investments a keyways: perspective, ability our January, in medicines. organizational of our focusing to the our first and that such, outside Core sales in second As are mapped of to United business research at AZ's European Lab's there with map immunoSEQ From is interest and believe receptors multiyear in lot We portfolio our business. improve portfolio partnership antigen T-MAP, is cancer entity from international two in to first, we are collaboration. play opening This States, capture want is stemming of expansion. to a immunosequencing support
data inside Secondly, sales marketing include monetization Kit are an and to our opportunities. business organization our team grow to colleagues more we expanding and
on with discovery in X. private and Genentech. speed T products shared both cell drug to ahead Slide full mediated on Moving Progress continues
shared with in quarter year. anticipated on include was second planned of by IND post first FDA the file Genentech productive FDA, filing. additional to that the requested initially Genentech Based this the the the we quarter information the decided had in first by interactions For for to submission product,
the for shared CCRs by product, shared promising For characterized have the Genentech development being considered currently product. second its several second we of
using data this shared We TCR is complete package result second potential a by Genentech, this of this if approach. our expect selected candidate the development TCR in to our second year. TruTCR could product And
we've targets of prioritized addition, against pipeline with Genentech. to candidates TruTCR continue we In that build additional our
tumor against patient. each TCRs product, private we identifying cancer mutations and the screening specific started have from using blood patient For specific
on We be lab an opened will to Genentech QX cancer personalized second track additional half samples a of To product the our from patients that and space XX product This private during deliver end from data of year. quarter. will will accommodate this additional results a we These dedicated building are our workflow. proof-of-concept are scale by to this end-to-end initial to be the development, patient a prototype establish by XXXX. used cancer
space this capacity Importantly, clinical early the accommodate studies. phase to has
growing purpose. process FTEs for also We our process and dedicated teams of are the and development this product in hiring
As Genentech. on now progress lots ahead XX. exciting parts can Using our virus. in partnership neutralizing to you see, of of Slide approach, the lead our milestones with bind and that our antibody discovery several antibodies Switching identified TruAB different antibody candidates we to strongly
mechanisms bind inhibit This candidates not important Our advantages Trimer, and the growing to include portfolio only RBD but antibodies varin. that strategy the region, that and potentially virus SX. virus have different of targets also novel to pactual of could in bind to the SX, action
We are exploring who on a clinically of as solution potential variants. antibody believe approach. provide wake with success in applications partners discovery candidates future antibodies are Building relevant our similarly identifying additional SARS-CoV-X advancing our our of these the differentiated may TruAB first discussions we target, in that differentiated to our
part our we to antibodies Chad disorders, As pass diseases need. now who it identify growth strategy, provide autoimmune occurring, with I'll targets aim and you discovery particularly over fill against C, naturally infectious a can additional fully drug we human of financial in update. strong a to where will several unmet
